Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Levosulpiride→

Levosulpiride Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
23672-07-3
Molecular formula
C15H23N3O4S
Molecular weight
341.43 g/mol
Drug class
Substituted benzamidedopamine D2/D3 receptor antagonist with prokinetic and antipsychotic activity
Mechanism of action
Blocks dopamine D2-family receptors centrally and in the enteric nervous system. Peripheral D2 blockade in the myenteric and submucosal plexuses enhances cholinergic activity and gastrointestinal motility; central dopaminergic blockade contributes to its antipsychotic and antiemetic pharmacology.
Indications / reported uses
  • Symptomatic treatment of functional dyspepsia and selected upper gastrointestinal motility disorders where authorised.
  • Psychiatric use for selected psychotic disorders is product- and jurisdiction-specific.

Sources: https://www.torrentpharma.com/assets/1398_fb0cb18995.pdf · https://pmc.ncbi.nlm.nih.gov/articles/PMC10036984/ · https://pubmed.ncbi.nlm.nih.gov/?term=levosulpiride+prokinetic+mechanism · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Levosulpiride Environmental Risk Assessment (ERA) (the Levosulpiride ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.